<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04981613</url>
  </required_header>
  <id_info>
    <org_study_id>KYS2021-03-02-9</org_study_id>
    <nct_id>NCT04981613</nct_id>
  </id_info>
  <brief_title>Study on the Efficacy and Safety of a Novel Tripterygium Wilfordii Preparation in Reducing Proteinuria in Patients With Diabetic Nephropathy</brief_title>
  <official_title>RCT Study on the Efficacy and Safety of a Novel Tripterygium Wilfordii Preparation in Reducing Proteinuria in Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators designed a randomized parallel controlled clinical study, selected 98 cases&#xD;
      of diabetic nephropathy patients with urinary protein &gt; 1g, randomly assigned into the&#xD;
      Kunxian capsule + irbesartan group or irbesartan group, 48 weeks of treatment and follow-up,&#xD;
      reduced levels of urinary protein and effective relief time, remission rate as the main end&#xD;
      point, estimated glomerular filtration rate (eGFR) drop rate slope for secondary end points,&#xD;
      safety events were also collected. To evaluate the efficacy and safety of Kunxian capsule&#xD;
      combined with irbesartan in treatment of diabetic nephropathy compared with irbesartan alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changed levels of urinary protein, gram</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The effective remission time of urinary protein, day</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary protein remission rate, %</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour urinary protein quantity, gram</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary albumin/creatinine ratio</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR decline rate slope</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving end stage renal disease (ESRD) or requiring dialysis or kidney transplantation, or blood creatinine doubling, or renal death, or all-cause death, %</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of participants achieving end stage renal disease (ESRD) or requiring dialysis or kidney transplantation, or blood creatinine doubling, or renal death, or all-cause death, days</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by bone marrow suppression, %</measure>
    <time_frame>48 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by liver damage, %</measure>
    <time_frame>48 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by infection, %</measure>
    <time_frame>48 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by gastrointestinal reactions, %</measure>
    <time_frame>48 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by skin damage, %</measure>
    <time_frame>48 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by reproductive toxicity (menorrhea or amenorrhea or infertility), %</measure>
    <time_frame>48 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>irbesartan tablet (150mg qd or 300mg qd) for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kunxian capsule</intervention_name>
    <description>Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Conformed to the diagnostic criteria of diabetic nephropathy&#xD;
&#xD;
          -  No gender limitation, age 18-65 years old, no fertility requirement temporarily&#xD;
&#xD;
          -  eGFR: 30~90ml/min/1.73m2（CKD-EPI）&#xD;
&#xD;
          -  Urine protein &gt;1 g/day&#xD;
&#xD;
          -  No glucocorticoids or/and immunosuppressive therapy was received within 3 months&#xD;
&#xD;
          -  Patients volunteered to participate in this study and signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Combined with diabetic acute complications or acute kidney injury (AKI)&#xD;
&#xD;
          -  Combined with other autoimmune diseases&#xD;
&#xD;
          -  Primary and other secondary renal diseases&#xD;
&#xD;
          -  Patients with hypotension (BP &lt; 90/60mmHg) or bilateral renal artery stenosis who are&#xD;
             not suitable for angiotensin receptor blockers (ARB) drugs&#xD;
&#xD;
          -  There are contraindications to the use of kunxian capsules or allergic to any of the&#xD;
             ingredients in kunxian capsules&#xD;
&#xD;
          -  There are fertility requirements or pregnant, lactation patients&#xD;
&#xD;
          -  Combined with malignant tumor, hepatitis, tuberculosis, HIV, serious infection,&#xD;
             rheumatic disease, heart failure, chronic obstructive pulmonary disease (COPD) and&#xD;
             other serious systemic diseases&#xD;
&#xD;
          -  Kidney transplant or dialysis has been performed&#xD;
&#xD;
          -  Clinicians deem it inappropriate, or patients are unwilling to sign informed consent,&#xD;
             have poor compliance, have a history of mental illness, or cannot complete follow-up&#xD;
             visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yan Shen, MD, PHD</last_name>
    <phone>0086-18991978269</phone>
    <email>shenyan66@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan Ya Gao, MD</last_name>
    <phone>0086-15122036218</phone>
    <email>3167496249@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xian Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Shen, MD, PHD</last_name>
      <phone>0086-18991978269</phone>
      <email>shenyan66@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

